Evommune

Evommune is a biopharmaceutical company dedicated to discovering and developing innovative therapies aimed at treating chronic inflammatory diseases. Founded with the mission to address the devastating effects of chronic inflammation, the company focuses on targeting the root causes of these conditions through cutting-edge science.

With a robust pipeline that includes the MRGPRX2 antagonist EVO756 and an IL-18 targeted fusion protein, Evommune is actively advancing clinical trials to bring effective treatments to patients suffering from conditions such as chronic spontaneous urticaria and atopic dermatitis. The company is committed to making a significant impact in the field of chronic inflammation through its research and development efforts.

Generated from the website